Found: 22
Select item for more details and to access through your institution.
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01046-2
- By:
- Publication type:
- Article
Potential value of pre-planned imaging of bone disease in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00880-0
- By:
- Publication type:
- Article
Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population‐based study from the Danish national multiple myeloma registry
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 1, p. 119, doi. 10.1111/bjh.16806
- By:
- Publication type:
- Article
Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients.
- Published in:
- British Journal of Haematology, 2018, v. 183, n. 3, p. 375, doi. 10.1111/bjh.15521
- By:
- Publication type:
- Article
The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab‐containing line of therapy.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. E117, doi. 10.1002/ajh.26449
- By:
- Publication type:
- Article
A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma.
- Published in:
- Experimental Hematology & Oncology, 2018, v. 7, n. 1, p. N.PAG, doi. 10.1186/s40164-018-0110-0
- By:
- Publication type:
- Article
Geographical and ecological analyses of multiple myeloma in Denmark: Identification of potential hotspot areas and impact of urbanisation.
- Published in:
- European Journal of Haematology, 2023, v. 110, n. 3, p. 289, doi. 10.1111/ejh.13904
- By:
- Publication type:
- Article
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries.
- Published in:
- European Journal of Haematology, 2022, v. 108, n. 2, p. 99, doi. 10.1111/ejh.13707
- By:
- Publication type:
- Article
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.
- Published in:
- European Journal of Haematology, 2022, v. 108, n. 1, p. 34, doi. 10.1111/ejh.13709
- By:
- Publication type:
- Article
The real-world outcomes of multiple myeloma patients treated with daratumumab.
- Published in:
- PLoS ONE, 2021, v. 16, n. 10, p. 1, doi. 10.1371/journal.pone.0258487
- By:
- Publication type:
- Article
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 6, p. 2256, doi. 10.1002/cam4.1422
- By:
- Publication type:
- Article
The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study.
- Published in:
- Cancer Medicine, 2017, v. 6, n. 7, p. 1807, doi. 10.1002/cam4.1128
- By:
- Publication type:
- Article
Clarithromycin added to bortezomib‐cyclophosphamide‐dexamethasone impairs health‐related quality of life in multiple myeloma patients.
- Published in:
- European Journal of Haematology, 2019, v. 102, n. 1, p. 70, doi. 10.1111/ejh.13175
- By:
- Publication type:
- Article
P-167: Real-world elderly myeloma patients: improved survival despite more adverse risk factors than younger patients and RCT populations. A study on behalf of the Nordic Myeloma Study Group.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S127, doi. 10.1016/S2152-2650(21)02294-1
- By:
- Publication type:
- Article
Drug Response Prediction in High Risk Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e130, doi. 10.1016/j.clml.2017.03.235
- By:
- Publication type:
- Article
Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length.
- Published in:
- International Journal of Cancer, 2015, v. 136, n. 5, p. E351, doi. 10.1002/ijc.29101
- By:
- Publication type:
- Article
Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 521, doi. 10.1002/hon.2906
- By:
- Publication type:
- Article
Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: A study based on the nationwide Danish Multiple Myeloma Registry.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 10, p. E611, doi. 10.1002/ajh.24857
- By:
- Publication type:
- Article
Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma.
- Published in:
- British Journal of Haematology, 2012, v. 158, n. 6, p. 805, doi. 10.1111/j.1365-2141.2012.09244.x
- By:
- Publication type:
- Article
The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies.
- Published in:
- EJHaem, 2023, v. 4, n. 4, p. 1006, doi. 10.1002/jha2.774
- By:
- Publication type:
- Article
Serological tumor markers for small cell lung cancer and their therapeutic implications.
- Published in:
- APMIS, 1994, v. 102, n. 7-12, p. 561, doi. 10.1111/j.1699-0463.1994.tb05206.x
- By:
- Publication type:
- Article